Product category:
Genomics
News Release from: GE Healthcare | Subject: HitHunter
Edited by the Laboratorytalk Editorial
Team on 25 September 2003
Homogenous assays added
Product line features homogeneous assays for some of the most popular targets in drug discovery, such as G-protein coupled receptors, kinases, and nuclear hormone receptors
Amersham Biosciences has signed a distribution agreement with DiscoveRx for its HitHunter product line By adding the HitHunter homogeneous, non-radioactive assays to its portfolio, Amersham Biosciences now offers a full range of radiometric, fluorescent and chemiluminescent assay kits for a range of biological targets
This article was originally published on Laboratorytalk on 29 May 2006 at 8.00am (UK)
Related stories
Distribution agreement for HitHunter cAmp assays
HitHunter cAmp assays are homogeneous, non-radioactive, cell-based assays used to screen for G-protein coupled receptor (GPCR) activation in a microplate-based format
Tips to improve radiochemical safety
Contains reaction-sized aliquots of radionucleotide in a solution-free format, making experiments easier and safer to do
20,000 human genes in a single experiment
Bioarray can be used to identify up or down regulated genes involved in key biological processes including oncogenesis, metabolism, inflammation and apoptosis
The HitHunter products come with clear protocols and can be read on both plate readers, and imaging platforms such as Amersham Biosciences Leadseeker multimodality imaging system.
The product line features homogeneous assays for some of the most popular targets in drug discovery, such as G-protein coupled receptors (GPCRs), kinases, and nuclear hormone receptors.
The assays utilise proprietary enzyme fragment complementation technology which has a very sensitive, enzymatically-amplified signal as well as the flexibility to use a number of existing detection instruments.
John Sutton VP product management, bioassays at Amersham Biosciences says "We are delighted to have signed this distribution agreement with DiscoveRx.
"The HitHunter products extends the range of non-radiometric reagents and kits suitable for use on the Leadseeker multimodality imaging system, thus enabling Amersham Biosciences to meet the needs of our customers in the screening community.
"This agreement also allows Amersham Biosciences to offer a wider range of fully configured second messenger kits to our research customers".
"We are excited to be working with Amersham Biosciences", said Pyare Khanna, president, CEO, and founder of DiscoveRx.
"The proprietary technology from DiscoveRx and the marketing and support reach of Amersham Biosciences will give us a strong presence in the academic market as well as in high throughput screening in the pharmaceutical market.
"This depth of experience and technology should have tremendous synergy".
The HitHunter products now available from Amersham Biosciences include cAMP fluorescent and chemiluminescent kits suitable for 96 and 384 well plate formats.
An IP3 fluorescence polarisation kit and a cAMP kit with improved sensitivity will be launched shortly.
• GE Healthcare: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
